Sun Pharmaceutical Industries Ltd SUN.NS
* Says validation of regulatory filing of tildrakizumab with the european medicines agency (EMA) by Almirall.
* Tildrakizumab is an investigational IL-23P19 inhibitor being evaluated for the treatment of moderate-to-severe plaque psoriasis.
* Filing includes efficacy, safety data from pivotal phase III clinical trials that included over 1,800 patients Source text - Further company coverage: SUN.NS
